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T2 relaxation times corresponded to cervix tissue at 1.5T and 
3T.1,2 MRI scans were performed on a 1.5T Ingenia and a 3T 
Achieva Philips system using 2D Spin Echo (SE) and 3D Spoiled 
Gradient Echo (SPGR) sequences. CT scans were acquired 
using our standard clinical protocol and were used as the gold 
standard for applicator reconstruction. Geometrical 
distortion was quantitatively assessed after non-deformable 
MR to CT image registration.  
Results: On both 1.5T and 3T the multiplanar T2-weighted SE 
scans provided good soft tissue contrast. However, on 3T, the 
T2-weighted SE scans showed detrimental distortion artifacts, 
making them unsuitable for accurate anatomical delineation 
and applicator reconstruction. On 1.5T, these artifacts were 
significantly reduced and the image quality was expected to 
be adequate for delineation. For applicator reconstruction a 
new 3D sequence with an extremely short TE was developed 
called '3D_applicator', based on the SPGR sequence by Petit 
et al.3 The intrauterine and ovoid probes, as well as the 
needles were clearly visualized using this sequence (Figure 
1). The total scan time of the MRI protocol, consisting of a 
survey scan, three multiplanar T2-weighted SE scans and the 
'3D_applicator' scan, was less than 17 minutes. The specific 
absorption rate (SAR) of all sequences was amply below the 
limits set by the applicator manufacturer.  
 
Figure 1. CT and MRI ('3D_applicator' sequence at 1.5T) scans 
of the titanium applicator positioned in the gel phantom.  
Conclusions: For 1.5T MRI a high image quality scan protocol 
was developed that allows for accurate MRI-only based 
treatment planning of combined intracavitary and interstitial 
cervical brachytherapy with a titanium Fletcher-style 
applicator. For 3T, such a protocol remains to be established.  
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Radiotherapy is an important modality in the 
multidisciplinary approach towards cancer; and it is the 
vision of ESTRO for the 2020 horizon that “Every cancer 
patient in Europe will have access to state-of-the-art 
radiation therapy, as part of a multidisciplinary approach 
where treatment is individualized for the specific patient’s 
cancer, taking account of the patient’s personal 
circumstances” But how many patients should receive 
radiotherapy, and what is the current access to state-of-the-
art radiotherapy resources in the European countries? And 
how will these parameters evolve towards 2020? These topics 
are currently addressed in the ESTRO Health Economics in 
Radiation Oncology (HERO) project. HERO has the overall aim 
to develop a knowledge base of the provision of radiotherapy 
in Europe and build a model for health economic evaluation 
of radiation treatments at the European level. 
The current access to radiotherapy resources in Europe were 
recently documented by HERO in collaboration with the 
European national radiotherapy societies. High income 
countries especially in Northern-Western Europe are well-
served with radiotherapy resources; other countries are 
facing important shortages of equipment in general and 
especially machines capable of delivering high precision 
conformal treatments (IMRT, IGRT). Despite these variations, 
the results demonstrated a considerable positive evolution in 
radiotherapy resources since the ESTRO-QUARTS study in 
2005, with higher equipment levels and lower patient loads 
per unit of equipment or per radiotherapy professional than 
recommended a decade ago. This evolution has not been the 
same in all European countries, which to some degree explain 
the variation seen between countries. 
Planning for the optimal radiotherapy service on e.g. a 
national level is a challenge. First of all, detailed estimation 
of the projected need for radiotherapy, in terms of number 
of cancer patients requiring radiotherapy now and in the 
future, is required. This involves merging epidemiological 
data with evidence-based clinical decision trees. Secondly, 
solid data on the anticipated throughput (patients per 
machine, with relevant staff) is needed. Productivity and 
efficiency is variable from country to country, and is 
dynamically changing as novel techniques and equipment are 
introduced. Despite these challenges, early planning is 
needed as it takes several years from the decision to build or 
extend a radiotherapy facility is made to the first patient can 
be treated: equipment must be procured, installed and 
commissioned, and the staff properly educated. A 
particularly difficult example is planning for particle 
radiotherapy, where the indications and future needs are 
more uncertain, the capital costs higher and the construction 
times much longer than for conventional radiotherapy.   
The need for radiotherapy, expressed in terms of the 
proportion of cancer patients who will have an evidence-
based indication for radiotherapy, is not straightforward to 
assess. The Australian CCORE studies have indicated that 
about 50% of all cancer patients will at some point in their 
disease need radiotherapy. In a recent HERO study these 
estimates have been refined with details about tumor site 
and stage relevant for each of the European countries. The 
results indicate that 51% of the 3.4 million new European 
cancer patients in 2012 were candidates for radiotherapy. A 
comparison to the actually delivered radiotherapy courses 
published in the HERO studies revealed that the optimal 
benchmark is not met in the vast majority of countries, not 
even the most affluent and well-served countries.  
In conclusion, despite improvements in equipment and 
staffing there is today still a significant underutilization of 
radiotherapy in most European countries. Combined with the 
anticipated significant increase in new cancer cases over the 
next years, this unmet need represents a real challenge to 
the ESTRO vision for 2020. There is still a long way before 
every cancer patient in Europe will have access to state-of-
the-art radiotherapy.  
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